Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
96 hedge funds and large institutions have $201M invested in Adverum Biotechnologies in 2018 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 14 closing their positions.
436% more call options, than puts
Call options by funds: $3.96M | Put options by funds: $739K
229% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 14
198% more capital invested
Capital invested by funds: $67.3M → $201M (+$133M)
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
48% more funds holding
Funds holding: 65 → 96 (+31)
1.3% more ownership
Funds ownership: 4.27% → 5.57% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$11.6M |
| 2 |
JP Morgan Chase
New York
|
+$11.6M |
| 3 |
Alkeon Capital Management
New York
|
+$9.31M |
| 4 |
Millennium Management
New York
|
+$8.88M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$8.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.8M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.6M |
| 3 |
SC
Sessa Capital
New York
|
-$2.23M |
| 4 |
Two Sigma Investments
New York
|
-$2M |
| 5 |
6CM
683 Capital Management
New York
|
-$1.93M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MP
101
Mangrove Partners
Greenwich,
Connecticut
| – | -$1.49M | -42,454 | Closed |
|
102
Jennison Associates
New York
| – | -$1.06M | -30,208 | Closed |
|
|
JAM
103
JW Asset Management
Miami Beach,
Florida
| – | -$625K | -17,865 | Closed |
|
|
SIM
104
Spark Investment Management
New York
| – | -$233K | -6,682 | Closed |
|
|
RJA
105
Raymond James & Associates
St Petersburg,
Florida
| – | -$172K | -4,900 | Closed |
|
|
AGM
106
Alpine Global Management
New York
| – | -$72K | -2,071 | Closed |
|
|
DTL
107
Dynamic Technology Lab
Singapore
| – | -$36K | -1,033 | Closed |
|
108
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$20K | -565 | Closed |
|
109
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$8K | -240 | Closed |
|
|
MAM
110
Meeder Asset Management
Dublin,
Ohio
| – | -$5K | -155 | Closed |
|
ADVM Hedge Fund Activity: Q1 2018 in Review
96 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2018, worth a combined $201M — up 198% from $67.3M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ADVM positions and 14 closed out — a net gain of 32 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $11.6M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $2.8M sold.
- 96 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2018, up from 65 in Q4 2017.
- Funds reported $201M of Adverum Biotechnologies stock for Q1 2018, up 198% quarter-over-quarter.
- 46 funds opened new Adverum Biotechnologies positions in Q1 2018 and 14 closed out, a net change of +32 holders.
- The largest Adverum Biotechnologies buyer in Q1 2018 was Driehaus Capital Management, an estimated $11.6M added.
- The largest Adverum Biotechnologies seller in Q1 2018 was Rubric Capital Management (New York), an estimated $2.8M sold.
Based on aggregated 13F filings for Q1 2018.